{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:46:50Z","timestamp":1790275610174,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1007\/s00262-009-0751-2","type":"journal-article","created":{"date-parts":[[2009,8,11]],"date-time":"2009-08-11T06:03:51Z","timestamp":1249970631000},"page":"303-312","source":"Crossref","is-referenced-by-count":42,"title":["Polymorphisms in the CD28\/CTLA4\/ICOS genes: role in malignant melanoma susceptibility and prognosis?"],"prefix":"10.1007","volume":"59","author":[{"given":"Marna G.","family":"Bouwhuis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Gast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina","family":"Figl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M. M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,8,12]]},"reference":[{"key":"751_CR1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0065-2776(06)90006-6","volume":"90","author":"H Uchi","year":"2006","unstructured":"Uchi H, Stan R, Turk MJ, Engelhorn ME, Rizzuto GA, Goldberg SM, Wolchok JD, Houghton AN (2006) Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol 90:215\u2013241","journal-title":"Adv Immunol"},{"key":"751_CR2","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJM198806163182401","volume":"318","author":"MB Atkins","year":"1988","unstructured":"Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM (1988) Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318:1557\u20131563","journal-title":"N Engl J Med"},{"key":"751_CR3","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1200\/JCO.2001.19.15.3477","volume":"19","author":"GQ Phan","year":"2001","unstructured":"Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA (2001) Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19:3477\u20133482","journal-title":"J Clin Oncol"},{"key":"751_CR4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa053007","volume":"354","author":"H Gogas","year":"2006","unstructured":"Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A et al (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709\u2013718","journal-title":"N Engl J Med"},{"key":"751_CR5","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/jnci\/djp132","volume":"101","author":"MG Bouwhuis","year":"2009","unstructured":"Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, Stierner U, Sales F, Patel P, Punt CJ et al (2009) Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst 101:869\u2013877","journal-title":"J Natl Cancer Inst"},{"key":"751_CR6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.immunol.24.021605.090535","volume":"24","author":"WA Teft","year":"2006","unstructured":"Teft WA, Kirchhof MG, Madrenas J (2006) A molecular perspective of CTLA-4 function. Annu Rev Immunol 24:65\u201397","journal-title":"Annu Rev Immunol"},{"key":"751_CR7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","volume":"23","author":"RJ Greenwald","year":"2005","unstructured":"Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23:515\u2013548","journal-title":"Annu Rev Immunol"},{"key":"751_CR8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4049\/jimmunol.164.1.144","volume":"164","author":"LJ Appleman","year":"2000","unstructured":"Appleman LJ, Berezovskaya A, Grass I, Boussiotis VA (2000) CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J Immunol 164:144\u2013151","journal-title":"J Immunol"},{"key":"751_CR9","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature01621","volume":"423","author":"H Ueda","year":"2003","unstructured":"Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G et al (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506\u2013511","journal-title":"Nature"},{"key":"751_CR10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1399-0039.2004.00312.x","volume":"64","author":"SS Amundsen","year":"2004","unstructured":"Amundsen SS, Naluai AT, Ascher H, Ek J, Gudjonsdottir AH, Wahlstrom J, Lie BA, Sollid LM (2004) Genetic analysis of the CD28\/CTLA4\/ICOS (CELIAC3) region in coeliac disease. Tissue Antigens 64:593\u2013599","journal-title":"Tissue Antigens"},{"key":"751_CR11","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.humimm.2007.05.002","volume":"68","author":"JM Cozar","year":"2007","unstructured":"Cozar JM, Romero JM, Aptsiauri N, Vazquez F, Vilchez JR, Tallada M, Garrido F, Ruiz-Cabello F (2007) High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol 68:698\u2013704","journal-title":"Hum Immunol"},{"key":"751_CR12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cancergencyto.2005.07.020","volume":"165","author":"N Erfani","year":"2006","unstructured":"Erfani N, Razmkhah M, Talei AR, Pezeshki AM, Doroudchi M, Monabati A, Ghaderi A (2006) Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer. Cancer Genet Cytogenet 165:114\u2013120","journal-title":"Cancer Genet Cytogenet"},{"key":"751_CR13","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM et al (2001) Final version of the American Joint Committee on cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635\u20133648","journal-title":"J Clin Oncol"},{"key":"751_CR14","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1038\/sj.onc.1206462","volume":"22","author":"T Ramirez-Montagut","year":"2003","unstructured":"Ramirez-Montagut T, Turk MJ, Wolchok JD, Guevara-Patino JA, Houghton AN (2003) Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 22:3180\u20133187","journal-title":"Oncogene"},{"key":"751_CR15","doi-asserted-by":"crossref","unstructured":"Gogas H, Metaxas Y, Dafni U, Polyzos A, Fountzilas G, Pectasides E, Skarlos D, Tsoutsos D, Panagiotou P, Spyropoulou-Vlachou M et al (2008) Evaluation of CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon. J Clin Oncol 26: Suppl; abstr 9054","DOI":"10.1200\/jco.2008.26.15_suppl.9054"},{"key":"751_CR16","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.1158\/0008-5472.CAN-08-0806","volume":"68","author":"T Sun","year":"2008","unstructured":"Sun T, Zhou Y, Yang M, Hu Z, Tan W, Han X, Shi Y, Yao J, Guo Y, Yu D et al (2008) Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res 68:7025\u20137034","journal-title":"Cancer Res"},{"key":"751_CR17","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1002\/(SICI)1521-4141(199911)29:11<3596::AID-IMMU3596>3.0.CO;2-Y","volume":"29","author":"G Magistrelli","year":"1999","unstructured":"Magistrelli G, Jeannin P, Herbault N, Benoit De Coignac A, Gauchat JF, Bonnefoy JY, Delneste Y (1999) A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 29:3596\u20133602","journal-title":"Eur J Immunol"},{"key":"751_CR18","doi-asserted-by":"crossref","first-page":"46478","DOI":"10.1074\/jbc.M206894200","volume":"277","author":"S Anjos","year":"2002","unstructured":"Anjos S, Nguyen A, Ounissi-Benkalha H, Tessier MC, Polychronakos C (2002) A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J Biol Chem 277:46478\u201346486","journal-title":"J Biol Chem"},{"key":"751_CR19","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1365-2141.2005.05525.x","volume":"129","author":"G Piras","year":"2005","unstructured":"Piras G, Monne M, Uras A, Palmas A, Murineddu M, Arru L, Bianchi A, Calvisi A, Curreli L, Gaviano E et al (2005) Genetic analysis of the 2q33 region containing CD28-CTLA4-ICOS genes: association with non-Hodgkin\u2019s lymphoma. Br J Haematol 129:784\u2013790","journal-title":"Br J Haematol"},{"key":"751_CR20","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1200\/JCO.2005.05.5434","volume":"24","author":"TY Cheng","year":"2006","unstructured":"Cheng TY, Lin JT, Chen LT, Shun CT, Wang HP, Lin MT, Wang TE, Cheng AL, Wu MS (2006) Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 24:3483\u20133489","journal-title":"J Clin Oncol"},{"key":"751_CR21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/sj.gene.6363869","volume":"3","author":"XB Wang","year":"2002","unstructured":"Wang XB, Zhao X, Giscombe R, Lefvert AK (2002) A CTLA-4 gene polymorphism at position \u2212318 in the promoter region affects the expression of protein. Genes Immun 3:233\u2013234","journal-title":"Genes Immun"},{"key":"751_CR22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.humimm.2008.01.014","volume":"69","author":"K Suwalska","year":"2008","unstructured":"Suwalska K, Pawlak E, Karabon L, Tomkiewicz A, Dobosz T, Urbaniak-Kujda D, Kuliczkowski K, Wolowiec D, Jedynak A, Frydecka I (2008) Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia in the Polish population. Hum Immunol 69:193\u2013201","journal-title":"Hum Immunol"},{"key":"751_CR23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1744-313X.2008.00782.x","volume":"35","author":"F Dilmec","year":"2008","unstructured":"Dilmec F, Ozgonul A, Uzunkoy A, Akkafa F (2008) Investigation of CTLA-4 and CD28 gene polymorphisms in a group of Turkish patients with colorectal cancer. Int J Immunogenet 35:317\u2013321","journal-title":"Int J Immunogenet"},{"key":"751_CR24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1365-2370.2000.00198.x","volume":"27","author":"A Heinzmann","year":"2000","unstructured":"Heinzmann A, Plesnar C, Kuehr J, Forster J, Deichmann KA (2000) Common polymorphisms in the CTLA-4 and CD28 genes at 2q33 are not associated with asthma or atopy. Eur J Immunogenet 27:57\u201361","journal-title":"Eur J Immunogenet"},{"key":"751_CR25","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/CJI.0b013e31817fd8f3","volume":"31","author":"WB Breunis","year":"2008","unstructured":"Breunis WB, Tarazona-Santos E, Chen R, Kiley M, Rosenberg SA, Chanock SJ (2008) Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J Immunother 31:586\u2013590","journal-title":"J Immunother"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-009-0751-2.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,7]],"date-time":"2019-04-07T07:49:57Z","timestamp":1554623397000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-009-0751-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,12]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["751"],"URL":"https:\/\/doi.org\/10.1007\/s00262-009-0751-2","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,12]]}}}